Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

April 26 2018 Women and girls of childbearing potential must no longer take valproate medicines...

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

April 23 2018 Buprenorphine has been found to have lower rates of overdose death than methadone...

Class of diabetes drug linked to increased risk of irritable bowel disease

Class of diabetes drug linked to increased risk of irritable bowel disease

March 29 2018 A study has shown that dipeptidylpeptidase-4 inhibitors may increase the risk of...

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

March 29 2018 Mefloquine is safe to use for malaria prevention during pregnancy, a Cochrane...

  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:08
  • Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Thursday, 26 April 2018 11:48
  • Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Monday, 23 April 2018 16:48
  • Class of diabetes drug linked to increased risk of irritable bowel disease

    Class of diabetes drug linked to increased risk of irritable bowel disease

    Thursday, 29 March 2018 11:27
  • Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Thursday, 29 March 2018 11:21

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageOctober 31 2017

The medicines regulator has issued four drug safety updates (DRU) relating to gabapentin methylprednisolone clozapine isotretinoin.

The MHRA’s warning on gabapentin says the people taking the drug, used in epilepsy and peripheral neuropathic pain, have “a rare risk of severe respiratory depression even without concomitant opioid medicines.” Dose adjustments may be necessary in a number of patient groups: those with compromised respiratory function; respiratory or neurological disease; renal impairment; concomitant use of central nervous system (CNS) depressants; and the elderly.

The warning around methylprednisolone relates to Solu-Medrone 40mg injection. This strength uses lactose produced from cows’ milk as an excipient and may contain trace amounts of milk proteins.

“Do not use injectable methylprednisolone medicines that contain lactose in patients with a known or suspected allergy to cows’ milk,” says the DSU. “If a patient’s symptoms worsen or any new allergic symptoms occur, allergic reaction to cows’ milk proteins should be suspected; stop administration of the product and treat the patient’s condition accordingly.”

Constipation occurring with clozapine needs to be monitored, says the third DSU. The antipsychotic has been associated with varying degrees of impairment of intestinal peristalsis, ranging from “constipation, which is very common, to very rare intestinal obstruction, faecal impaction, and paralytic ileus.”

Particular care is needed in patients who taking other drugs known to cause constipation, in patients with a history of colonic disease or lower abdominal surgery, or in patients aged 60 years and older. Clozapine should not be used in patients with paralytic ileus.

Patients who develop constipation should report it immediately, and health professionals should “actively treat any constipation that occurs.”

The isotretinoin DSU advises that there have been some reports of sexual dysfunction, especially erectile dysfunction and loss of libido, in patients taking oral isotretinoin for severe acne. “The exact incidence of these adverse reactions is unknown but considering the number of patients in the UK taking the medicine, reports are understood to be rare,” says the MHRA.

For all drugs, the MHR is asking that any suspected adverse reactions be reported using eth Yellow Card scheme.

Links:
MHRA DSU on gabapentin           
MHRA DSU on methylprednisolone          
MHRA DSU on clozapine                 
MHRA DSU on isotretinoin             
Yellow Card scheme        

Clinical News

May 22 2018 A “bespoke, fully funded independent prescribing course for community pharmacists in NHS Scotland” has been announced by Community Pharmacy Scotland.
May 21 2018  NHS England and Capita’s handling of primary care support services has been criticised in an official report. The National Audit Office has published a review saying that “NHS England and...